TrialJournal of acquired immune deficiency syndromes (1999)2018

Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.

Sally Hodder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.